IJCM  Vol.10 No.11 , November 2019
Hepatitis B Reactivation in Patients with Hematological and Solid Malignancies: A Retrospective Analysis of Single Center’s Experience
Abstract: Background: Hepatitis B reactivation might occur in patients with hematological and solid organ malignancies due to immunosuppressive effect of chemotherapy. Methods: Fourteen patients were evaluated retrospectively from their files to discuss the clinical manifestations, management, and avoiding of Hepatitis B reactivation within patients who receive immunosuppressive treatment. Results: These 14 HbsAg positive patients were being followed up and treated via oncological immunosuppressive chemotherapy. The ages of the patients were between 25 and 72. Seven of the patients were male, and the average follow up period for the patients was between 10 and 74 months. TV 0, 5 mg was started for seven of the patients before the chemotherapy and TFV 245 mg to one of the patients. LAM 100 was started for three patients whose basal HBV DNA was low. It has been analyzed that HBV DNA was negative in further observations. In follow up controls, we noticed HBV reactivation at two patients, LAM was given one of them and TFV was given the other one. One patient was applied allogeneic transplantation whose basal liver tests were normal and Hbsag was negative. Hepatitis B reactivation was detected after the first week of therapy. Conclusions: We offer testing in all patients undergoing cancer therapy for hepatitis B, HBsAg, core antibody (anti-HBc total), and anti-HBs before to start cancer therapy. Patients with higher risk of HBV reactivation require antiviral prophylaxis.
Cite this paper: Yakut, M. , Demir, Z. , Ekinci, A. and Yakut, F. (2019) Hepatitis B Reactivation in Patients with Hematological and Solid Malignancies: A Retrospective Analysis of Single Center’s Experience. International Journal of Clinical Medicine, 10, 622-629. doi: 10.4236/ijcm.2019.1011051.

[1]   Lok, A., Bonis, P. and Esteban, R. (2017) Hepatitis B Virus Reactivation Associated with Immunosuppressive Therapy.

[2]   Aygen, B., Demir, A.M., Gümüş, M., Karabay, O., Kaymakoğlu, S., Köksal, A.Ş., Köksal, İ., Örmeci, N. and Tabak, F. (2018) Immunosuppressive Therapy and the Risk of Hepatitis B Reactivation: Consensus Report. Turkish Journal of Gastroenterology, 29, 259-269.

[3]   Kim, M.K., Ahn, J.H., Kim, S.B., Im, Y.S., Lee, S.I., Ahn, S.H., Son, B.H., Gong, G., Kim, H.H. and Kim, W.K. (2007) Hepatitis B Reactivation during Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution’s Experience. The Korean Journal of Internal Medicine, 22, 237-243.

[4]   Gupta, S., Govindarajan, S., Fong, T.L. and Redeker, A.G. (1990) Spontaneous Reactivation in Chronic Hepatitis B: Patterns and Natural History. Journal of Clinical Gastroenterology, 12, 562.

[5]   Galbraith, R.M., Eddleston, A.L., Williams, R. and Zuckerman, A.J. (1975) Fulminant Hepatic Failure in Leukaemia and Choriocarcinoma Related to Withdrawal of Cytotoxic Drug Therapy. The Lancet, 2, 528-530.

[6]   Kumagai, K., Takagi, T., Nakamura, S., Sawada, U., Kura, Y., Kodama, F., Shimano, S., Kudoh, I., Nakamura, H., Sawada, K. and Ohnoshi, T. (1997) Hepatitis B Virus Carriers in the Treatment of Malignant Lymphoma: An Epidemiological Study in Japan. Annals of Oncology, 8, 107-109.

[7]   Lau, G.K., He, M.L., Fong, D.Y., Bartholomeusz, A., Au, W.Y., Lie, A.K., Locarnini, S. and Liang, R. (2002) Preemptive Use of Lamivudine Reduces Hepatitis B Exacerbation after Allogeneic Hematopoietic Cell Transplantation. Hepatology, 36, 702-709.

[8]   Rossi, G., Pelizzari, A., Motta, M. and Puoti, M. (2001) Primary Prophylaxis with Lamivudine of Hepatitis B Virus Reactivation in Chronic HbsAg Carriers with Lymphoid Maligna Ncies Treated with Chemotherapy. British Journal of Haematology, 115, 58-62.

[9]   Liaw, Y.F., Leung, N., Guan, R., Lau, G.K., Merican, I., McCaughan, G., Gane, E., Kao, J.H. and Omata, M. (2005) Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B: A 2005 Update. Liver International, 25, 472-489.

[10]   Lau, G.K., Yiu, H.H., Fong, D.Y., Cheng, H.C., Au, W.Y., Lai, L.S., Cheung, M., Zhang, H.Y., Lie, A., Ngan, R. and Liang, R. (2003) Early Is Superior to Deferred Preemptive Lamivudine Therapy for Hepatitis B Patients Undergoing Chemotherapy. Gastroenterology, 125, 1742-1749.

[11]   Yeo, W., Chan, P.K., Ho, W.M., Zee, B., Lam, K.C., Lei, K.I., Chan, A.T., Mok, T.S., Lee, J.J., Leung, T.W., Zhong, S. and Johnson, P.J. (2004) Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. Journal of Clinical Oncology, 22, 927-934.

[12]   Ahn, J.H., Kim, S.B., Yun, M.R., Lee, J.S., Kang, Y.K. and Kim, W.K. (2004) Alternative Therapy and Abnormal Liver Function during Adjuvant Chemotherapy in Breast Cancer Patients. Journal of Korean Medical Science, 19, 397-400.

[13]   Yeo, W., Zee, B., Zhong, S., Chan, P.K., Wong, W.L., Ho, W.M., Lam, K.C. and Johnson, P.J. (2004) Comprehensive Analysis of Risk Factors Associating with Hepatitis B Virus (HBV) Reactivation in Cancer Patients Undergoing Cytotoxic Chemotherapy. British Journal of Cancer, 90, 1306-1311.

[14]   Wood, W.C., Muss, H.B., Solin, L.J. and Olopade, O.I. (2005) Infections in the Cancer Patient. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A., Eds., Cancer: Principles & Practice of Oncology, 7th Edition, Lippincott Williams and Wilkins, Philadelphia, 1446-1447.

[15]   Levine, M. and Eisen, A. (2001) Anthracycline Adjuvant Chemotherapy: How Much Is Enough? Journal of Clinical Oncology, 19, 599-601.

[16]   Fumoleau, P., Kerbrat, P., Romestaing, P., Fargeot, P., Bremond, A., Namer, M., Schraub, S., Goudier, M.J., Mihura, J., Monnier, A., Clavere, P., Serin, D., Seffert, P., Pourny, C., Facchini, T., Jacquin, J.P., Sztermer, J.F., Datchary, J., Ramos, R. and Luporsi, E. (2003) Randomized Trial Comparing Six versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10 Year Follow-Up Results of the French Adjuvant Study Group 01 Trial. Journal of Clinical Oncology, 21, 298-305.

[17]   Yeo, W., Ho, W.M., Hui, P., Chan, P.K., Lam, K.C., Lee, J.J. and Johnson, P.J. (2004) Use of Lamivudine to Prevent Hepatitis B Virus Reactivation during Chemotherapy in Breast Cancer Patients. Breast Cancer Research and Treatment, 88, 209-221.

[18]   Hammond, S.P., Borchelt, A.M., Ukomadu, C., et al. (2009) Hepatitis B Virus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 15, 1049.

[19]   Tozun, N., Ozdogan, O., Cakaloglu, Y., et al. (2015) Seroprevalence of Hepatitis B and C Virus Infections and Risk Factors in Turkey: A Fieldwork TURHEP Study. Clinical Microbiology and Infection, 21, 1020-1026.

[20]   Pei, S.N., Ma, M.C., Wang, M.C., et al. (2012) Analysis of Hepatitis B Surfaceantibody Titers in B Cell Lymphoma Patients after Rituximab Therapy. Annals of Hematology, 91, 1007-1012.

[21]   Cho, Y., Yu, S.J., Cho, E.J., et al. (2016) High Titers of Anti-HBs Prevent Rituximab-Related Viral Reactivation in Resolved Hepatitis B Patient with Non-Hodgkin’s Lymphoma. Journal of Medical Virology, 88, 1010-1017.

[22]   Salpini, R., Colagrossi, L., Bellocchi, M.C., et al. (2015) Hepatitis B Surfaceantigen Genetic Elements Critical for Immune Escape Correlate with Hepatitis B Virus Reactivation upon Immunosuppression. Hepatology, 61, 823-833.

[23]   Gonzalez, S.A. and Perrillo, R.P. (2016) Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. Clinical Infectious Diseases, 62, 306-313.

[24]   Lee, Y.H., Bae, S.-C. and Song, G.G. (2013) Hepatitis B Virus (HBV) Reactivation in Rheumatic Patients with Hepatitis Core Antigen (HBV Occult Carriers) Undergoing Anti-Tumor Necrosis Factor Therapy. Clinical and Experimental Rheumatology, 31, 118-121.

[25]   Reddy, N.M. and Savani, B.N. (2013) Hepatitis B Reactivation in Patients with Hematological Malignancies and Stem Cell Transplantation. Journal of Blood and Lymph, 4, 114.

[26]   Shang, J., Wang, H., Sun, J., et al. (2016) A Comparison of Lamivudine Vsentecavir for Prophylaxis of Hepatitis B Virus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Single-Institutional Experience. Bone Marrow Transplant, 51, 581-586.

[27]   Paul, S., Dickstein, A., Saxena, A., et al. (2017) Role of Surface Antibody in Hepatitis B Reactivation in Patients with Resolved Infection and Hematologic Malignancy: A Meta-Analysis. Hepatology, 66, 379-388.

[28]   Hsu, C., Tsou, H.-H., Lin, S.-J., et al. (2014) Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients with Resolved HBV Infection: A Prospective Study. Hepatology, 59, 2092-2100.